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PERSONALIZED MEDICINE & RACE-BASED
DRUG DEVELOPMENT: ADDRESSING
MINORITY HEALTH CARE DISPARITIES
IN AN ETHICALLY CHARGED AREA
MICHAEL B. Losow, EsQ.*
Thank you. I would like to start by saying that any of the nice
slides you see in here I owe directly to Doctor Francis Collins,1
who has just recently done a similar speech and lent me his slide
show. One of the things you learn in law school is that you are
supposed to be prepared, but, as you see, as I go through the
slides that I put together, they are not really well designed, and I
did not have quite enough time to put background time in that I
was hoping to do. So, whenever you see something nice, I will
probably refer to Doctor Collins again.
Before even getting into my speech, I could probably spend all
my time talking about Doctor Jesty's presentation because there
are so many ethical issues that are raised therein, and the FDA
issues have all been in the news. Last summer an issue hit the
news: the race-based development of drugs. I am going out of
order of my speech now, but I do want to give you the background
of how I started working on this and why this issue has become
so important. Last July, one of BIO's 2 companies, NitroMed, 3
These remarks are an actual transcript of the author's comments at the St. John's
Journal of Legal Commentary Symposium on Feb. 25, 2005.
1 See Stephanie Schorow, Museum of Science Honors Chief of Genome-Map Effort,
BOSTON HERALD, Mar. 10, 2003, at 10 (reporting on Dr. Collins, director of the National
Human Genome Research Institute, and his receipt of the 2003 Walker Prize).
2 See generally NitroMed to Give Presentations at the 7th Annual BIO CEO & Investor
Conference, BUS. WIRE, Feb. 22, 2005 (announcing that NitroMed's President and CEO,
Michael D. Loberg, Ph.D., will be making two presentations at the BIO CEO & Investor
Conference).
3 See Boston Scientific and NitroMed Extend Collaboration on the Development of
Nitric Oxide Coated Stents; Companies Extend Development Agreement for Two Years,
Bus. WIRE, Jan. 8, 2004 (noting "NitroMed is an emerging pharmaceutical company that
discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the
therapeutic benefits of the naturally occurring molecule nitric oxide").
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was doing a clinical trial on a product called BiDil® that was
geared for African Americans with heart failure. The trial was
stopped because the FDA considered it unethical to give people a
placebo when the product was so good. Forty three percent of the
African American people using the product were recovering from
heart failure, but not just surviving heart failure: they were
recovering and living normal lives, being able to go back to work
and do things. This was extraordinary because, in general, most
heart failure products did not help African Americans. That drug
was the first drug of its category to help African Americans with
heart problems. When news of this hit the public, the response
was not: "Wow, this is fantastic, we're going to save more than
ten thousand lives of Americans every year." It was, "How can a
company make a product for a single race?" So, that is when I
started getting involved with this issue and started looking at
several things. I want to address several things, including the
following questions. What is race? What is race to the scientist?
What is race and how do we deal with it? NitroMed's trial, in
particular, was based on probably the worst definition of race, yet
they had scientific grounds for using race as a basis.
I also am going to apologize. I am going to read some of this
which is the way I dislike to give presentations most of all.
Maybe I should give you some disclosure. I am not just the
president of this hair club for men, but I am also a member. I am
a cancer survivor who was saved by biotechnology and hence I
am a strong believer in this stuff. Anyway, one of the side results
of chemotherapy is that my recall is not what it used to be, so
that is why I am going to be relying on my notes.
We know that minorities are disproportionately affected by
heart disease. They are disproportionately affected by major
disease areas, for instance, heart disease, cancer, diabetes, HIV.4
We also know that timely, appropriate treatment is not often
provided to minorities. I believe that biotechnology will lead the
scientific revolution to identifying the best scientific treatments
without regard to race, culture or socioeconomic conditions.
There should be no scientific rationale for health care treatment
4 See Public Health: GSK, ABC Radio, and DHHS to Improve Health Among
Communities of Color, AIDS WKLY., June 30, 2003, at 31 (noting that racial and ethnic
minorities are disproportionately affected by HIV/AIDS, cancer, heart disease, diabetes,
and asthma).
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disparities. As personalized medicine becomes the norm, we
must ensure that science and research include the widest range
of genetic diversity that will lead to better treatments for
everyone. In fact, we are at the dawn of an age of science and
medical treatment where the old social constructs of race will
have no place and no meaning. Different treatment can be
eliminated in the practice of medicine as a result of what we are
learning from genetics and the development of biomarkers, which
are biological molecules that indicate a particular disease, a
particular disease state or indicators of a response to treatments.
Before going into more detail, I would like to lay some
groundwork, define some terms for you, and the next five slides
will kind of lay out the background of some of the disparities.
African American women are twice as likely to die of cervical
cancer as are white women. 5 African American women are also
more likely to die of breast cancer than are women of any age or
other racial or ethnic group.6 African American seniors are
almost four times less likely than Caucasians to receive coronary
bypass surgery, and African Americans are two and a half times
more likely to die from heart failure than Caucasians.7 HIV
prevalence in African American women is twenty four times that
of white women, and African American men are eight times as
likely as white men to be diagnosed with HIV.8 Latinos, Native
Americans, African Americans, and certain Asian Pacific
Islander groups all have rates of diabetes far exceeding
Caucasians, and Hispanic Latino Americans are one and a half
times more likely to have diabetes than non-Hispanic whites. 9
5 See Patricia Guthrie, Cancer Project Aims to Save Women's Lives, ATL. J.-CONST.,
Aug. 13, 2004, at 1B (noting that "[lack of access to quality health care and private health
insurance, along with other poverty-related factors, diet, lifestyle and exposure to
environmental toxins are cited as possible reasons for the black-white cancer disparity").
6 See Breast Cancer: Women Focused on the Present are Less Likely to Have
Mammograms, WOMEN'S HEALTH WKLY., Sept. 18, 2003, at 38 (suggesting that learning
why African-American women delay receiving a mammography might lead to more
effective measures to overcome statistical disparity).
7 See Are Drugs Color Blind?, TIME, Nov. 22, 2004, at 100 (commenting that
"superficial differences like skin color explain far less than was once thought").
8 See Health Care For All, Statistics on Health Disparities, http://www.hcfama.org/
index.cfm?fuseaction=Page.viewPage&pageId=286 (last visited Nov. 16, 2005) (listing
national statistical disparities for various categories of disease).
9 See Rep. Crowley Sends Letter Urging CDC to Abandon Plans to Eliminate Office of
Minority Health, U.S. FED. NEWS, July 26, 2004 (noting that African-Americans have
heart disease mortality rates forty percent higher than whites).
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African American seniors are nearly two times less likely to
receive treatment for prostate cancer. 10
So, those statistics show clearly that disparities exist
concerning race and disease. You generally hear of it and have a
sense for it, but there are so many statistics out there. This is a
major problem, and there are many reasons for disparities and I
will get into that later as well.
What I would also like to do now is define some terms. First,
personalized medicine is kind of the rage - what people are
talking about. BIO, the Biotechnology Industry Organization,
just had an investor's conference in New York City the past three
days. At nearly every session the two issues discussed were
personalized medicine and drug safety in light of the Vioxx®
issues. I would also like to say, to distinguish biotechnology, that
BIO is a trade association. We represent nearly a thousand
biotech companies. Those include the big pharmaceutical
companies, such as Pfizer and Merck, but also, small companies
like NitroMed.
We like to think of biotechnology products, in general, as novel
products that have a major impact. Most of our companies that
have products out there started with orphan products, or drugs
for diseases of less than two hundred thousand people. These are
products that save lives; for instance, children with Cystic
Fibrosis used to die before age ten; the average life span now is
mid thirties and is ever-increasing.11 Another example is
Gaucher's Disease, which used to be a killer; however, there is
now a product that keeps children with said disease alive to
adulthood and living near normal lives. So, these are ground-
breaking products. They are not kind of a Vioxx® compared to
an aspirin. These are new and novel products.
So, what is personalized medicine? Let me first tell you what
it is not. It is not you going into your doctor, who comes up with
a specific drug to treat just you, although in certain instances
there might be something similar to that. There are researchers
10 See Hon. Elijah E. Cummings, Life and Death in America's Health Care System:
Giving our Private Sorrows a Stronger Public Voice, BALT. AFRO-AMER. NEWS, March 30,
2003 (asserting that African American seniors are more likely to have lower limbs
amputations due to diabetes).
11 See Expensive Drugs for Rare Illnesses Increase Pinch for State Aid Pediatric
Health Care, OBESITY, FITNESS & WELLNESS WEEK, Mar. 12, 2005 (noting that median
life expectancy of cystic fibrosis is thirty three years old).
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looking at cancer vaccines that will take your cancer tumor and
turn it into a vaccine that they put back into you, which will then
kill the tumors in your system. But that is not really what most
personalized medicine is about. According to Personalized
Medicine Coalition, (personalizedmedicinecoalition.org),12
personalized medicine uses new methods of molecular analysis to
better manage a patient's disease or predisposition toward a
disease. It aims to achieve optimal medical outcomes by helping
physicians and patients choose the disease management
approaches likely to work best in the context of a patient's
genetic and environmental profile. The question is: why do we
need personalized medicine? Currently, fifteen to thirty five
percent of blood pressure patients receive no benefit from blood
pressure medicine that exists. 13 Twenty to fifty percent of
patients who need anti-depressants receive no benefit from the
anti-depressants that are out there.14 Doctors will not know until
they give it to you whether you are going to receive a benefit from
that drug being administered to you. If there is a way to identify
the people who will benefit from a drug, you can then only give
the appropriate drug to the appropriate person. This shows what
personalized medicine can do.
Biotechnology is using newfound knowledge in genetics to
produce new approaches to therapies and cures. In the not-so-
distant future, our genetic profile will be a major component of
health assessment and care. One key here is risk prediction. We
can read your genetic profile to determine your risk for certain
diseases and then give you an idea of what to do. So, you can do
a colonoscopy starting at age forty; if you have a high risk for
colon cancer, you can specifically avoid a high fat diet from that
point on. Second, we have the phenomenon of
pharmacogenomics. Under this, a doctor can provide a dose to a
patient based on a particular genetic profile. So, again, for an
12 Personalized Medicine Coalition, http://www.personalizedmedicinecoalition.org
(last visited Nov. 16, 2005) (detailing mission as benefiting patients by advancing
understanding of personalized medicine).
13 See generally Barry Meier, Health Groups Urge More Drug Reviews, INT'L HERALD
TRIB., Dec. 30, 2004, at 15 (discussing ongoing struggle of doctors to determine which
drugs provide effective treatment for patients, including those targeting blood pressure).
14 See generally Mark Hovit, A Shadow of Doubt: Medical Schools Give Too Much
Control to Drug Firms When Testing Medications, Critics Say, FORT WORTH STAR-
TELEGRAM, Jan. 16, 2005, at Al (suggesting that drug firm control over medication
testing often minimizes results indicating that antidepressants do not work).
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anti-depressant, if you know someone's genetic profile, a doctor
can give that person the right drug and the right amount of it.
And we can develop new therapies, for example, gene based
drugs for therapy for cancer or for heart disease.
Biotechnology seeks to understand the genetic factors of
disease which can dramatically change health outcomes, while
freeing us of ethnicity-based categories of evaluating risks. This
is supposed to be about race-based development, but it also can
dramatically change health outcomes generally. Such
approaches include genetic screening programs that more
precisely diagnose diseases or help physicians select the type and
dose of medication best suited to certain groups of patients.
Biotechnology is developing better and targeted medical
treatment opportunities. Even today, when the FDA approves a
product, it is not really approving a product for everybody in that
category. One example is lymphoma; there are now many types
of lymphoma, so when a product is approved, for example, a
radiopharmaceutical, it is radiation treatment that's carried
through a monoclonal antibody, that is a drug that goes through
the system, and the radiation attacks just the tumor. It avoids
full body radiation that people have had in the past and all the
side effects that go with it. But it is only approved for certain
types of lymphomas.
Through genetics and advances in biotechnology, we will
develop drugs that are more effective to segments of the
population. Drugs will be targeted toward sex and gender,
recognizing differing responses to treatments. Drugs will be
targeted toward race, but hopefully down the road, not race in
the current social context of skin color, but in a more real
meaning, geographical ancestry type of context. For example,
people with East African ancestry tend to be slower metabolizers
of drugs.1 5 Personalized medicine is the way we manage a
patient's disease or predisposition to a disease.
Biotechnology is using pharmacogenomics and
pharmacogenetics. Pharmacogenomics is the study of all the
15 See Joan Arehart-Treichel, Experts Shine Spotlight on Racial Differences in Illness,
PSYCHIATRIC NEWS, Jan. 5, 2001, available at http://www.psych.org/pnews/01-01-
05/racial.html (reporting that one third of African Americans seem to be slow drug
metabolizers).
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genes to determine drug behavior.16 Pharmacogenetics is the
study of inherited differences in drug metabolism and your
response.17 With genetic screening, we will be able to more
precisely diagnose diseases and sub types. From what we learn,
we will utilize a patient's genetic and environmental profile to
select the treatment in the drug therapies including the type and
dose of medication. While we are decades away from a fully
realized world of personalized medicine, we are already seeing
the benefits.
Genetics play a role in the response to drugs as well.
Oncologists now use a genetic test to determine which children
with leukemia are likely to have a potentially fatal reaction to
the standard dose of commonly used chemotherapy, and adjust
the dose accordingly. They can test women with breast cancer to
determine which patients are likely to respond to a
chemotherapy drug called Herceptin®. Herceptin® is used for
patients who over express the HER-2 gene. With the product
Herceptin®, there is a diagnostic test that is given first, and
again, the doctor can determine, only patients that over-express
HER-2 will get Herceptin®.
Similarly, we have already seen gene markers that predict
colon cancer and the treatment and the response for that as well.
We have seen remarkable progress in preventing diseases with
direct genetic links. Over the last three decades, the number of
Tay Sachs cases has been slashed by more than ninety five
percent thanks to genetic screening in those of Eastern European
Jewish descent. Tests for liver enzymes, for liver enzyme
variations critical to the metabolization of many drugs are on the
way. These variations, some of which are more prevalent in
Asians, other more prevalent in Caucasians, can result in
overdoses and toxic reactions to common drugs.
Researchers are also looking for genetic markers that makes
many African Americans more likely to respond to this
experimental heart failure drug. These and other products in the
16 See Victoria Griffith, Personalised Medicine: Keeping Us Alive is Good Business,
FIN. TIMES-FT.coM, Nov. 10, 2004 (defining pharmacogenomics as "understanding how
disease affects specific patients").
17 See Studies Have Investigated Genetic Variants and Response to Statin Therapy:
Coronary Heart Disease, HEART DISEASE WKLY, Mar. 13, 2005 (describing
pharmacogenetics as "exploring genetic polymorphisms that influence response to drug
therapy ' ).
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pipeline will help healthcare providers deliver the right drug to
the right patient in the right dose. So, the benefits of
personalized medicine are providing people with products that
will provide relief only if it's good for them. For those where it
will not have any impact, you would save a lot of time, you save a
lot of money, and you protect the patient from all the side effects
because there is no drug that is effective that also does not have
some side effects.
Before I go into the issue of race based drug development
anymore, I want to give a little background on some of the
industry and the impact of personalized medicine on
biotechnology product development. From start up until the
product is, approved, that is from the time a company submits an
independent new drug application, it takes between ten and
fifteen years to get approval from the FDA.18 On average, the
cost of a new product is a half a billion to - a fairly recent Tufts
University study said - as much as almost nine hundred million
dollars to develop a new product.19 From the time that you file
your IND with the FDA, your patent is running. Generally, and
although everybody has twenty year patent life for any product,
whether it is a widget or a drug, until your drug is approved,
your patent time is running out. So, there is very limited time,
between five and seven years, 20 for a company that invests all
this time and money to get back its money on a drug product as
well as make money - as most corporations are there to do.
The new motto of biotechnology or drug development, really, is
"biology over chemistry." Prior to the genome sequencing in 2000,
there were five hundred proteins, enzymes, and biochemical
compound targets that our companies looked at and tried to have
an impact on. Since 2000, there are now ten thousand targets.
18 See Tufts Center for the Study of Drug Development, Innovative R&D Strategies
Remain Key to Developing New Medicines, Jan. 5, 2005, http://csdd.tufts.edu/NewsEvents/
RecentNews.asp?newsid-51 (indicating that new prescription medication can take up to
fifteen years to develop and obtain FDA approval).
19 See Tufts Center for the Study of Drug Development, Outlook 2005, available at
http://csdd.tufts.edu/InfoServices/OutlookPDFs/Outlook2OO5.pdf (last visited Nov. 16,
2005) (noting costs as of 2002 at level of $802 million for complete process of development
through application approval).
20 See generally Dennis S. Fernandez & James T. Huie, Strategic Balancing of Patent
and FDA Approval Processes to Maximize Market Exclusivity, available at
http://www.iploft.com/PTO-FDA.pdf (last visited Nov. 16, 2005) (discussing essential
nature of patents in biotechnology field in relation to obtaining market exclusivity,
resulting profit returns, and maximal company value).
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The old business model for the drug industry was creating a
blockbuster drug, and then to get rich off of that. The new model
is targeting or tailoring products to a specific patient group.
Treatments, these drug companies hope, will cover ninety
percent of the disease based on genetic profiles and ten percent
will be tailored to specific patients. But we are talking about
smaller and smaller subsets of the population, so you are not
talking blockbuster drugs anymore that can be used on everyone.
So, the question is how do you build economies of scales for these
smaller markets? And, getting now into our discussion, will
personalized medicine actually increase or decrease disparities
for minorities?
Here, I would like to again address the race issue. How do you
define race? And when you are doing drug development, in
general, do you include minorities in your trials? The reality is
most companies have done race-based drug development without
calling it that, because minorities generally are not included in
clinical trials. So, we are doing drug development for the white
population - even if it is unintentional. Most of the time it is
unintentional because of the high cost of clinical trials; that is
one of the most costly, if not the most costly part of developing a
drug product. It takes a long time to get people into clinical
trials. It costs companies a lot of money to find people to do
clinical trials. For a variety of reasons, minorities do not
generally like to participate in clinical trials, so it costs the drug
companies even more to go out and recruit them. There is also
an economic disincentive because companies know that there is a
difference in metabolization based on race. For example, on the
classification of skin color, basically, African Americans with
certain ancestry will metabolize drugs slower. The drugs might
not have an impact on African Americans.
Frankly, with most heart drugs, there is even a sex-based
difference in response to drugs. Most heart drugs that have been
developed really do not help women, and until the 1990's, there
was no requirement that such drugs be tested on women. In fact,
it was often intentionally done that women were not included in
clinical trial studies. This is why we do not have the data on the
value of a lot of those earlier drugs for women. But if a company
knows that they are going to include minorities in drug trials,
this inclusion may devalue the end result because it will have
2005]
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less of an impact on the whole group that they are looking at.
Then a company might worry that the FDA will not approve the
drug because it will not be statistically significant enough for the
FDA to approve. This is opposed to, as I mentioned before,
BiDil® where forty-three percent of the African Americans saw
actual life-saving improvement from the heart drug. Forty-three
percent is an enormous percentage which is why the FDA
stepped in and said this is something really good. They are still
going through the process and that drug will be up for approval
this June, actually.
So, these two women, Doctor Royal and Doctor Dunston, from
the Howard University Human Genome Project, stated that
knowledge from the human genome project and research on the
genome variation increasingly challenged the applicability of the
term "race" to human population groups, raising questions about
the validity of inferences made about race in the biomedical and
scientific literature. 21 And, again, most of what they are referring
to is skin color race as we define in society when we walk down
the road. We notice, "Oh, that person is Asian, that person is
Black," and they're categorized in that race.
As background, Howard University has had its National
Human Genome Center 22 investigating and sharing their DNA
sequence variation findings and the implication for treatment of
diseases common in African Americans. They are creating a
database of genetic material that they hope will eventually
include seventy-five hundred individuals. Just as an aside, as we
look at genetics and as we do research, one of the reasons
Howard decided to do this was to make sure that African
American genetics were profiled. Because of the industry and
the government requirements in Japan, we do know at least
there will be a fair amount of profiling of Asian genetics, but
21 See National Human Genome Center at Howard University, State of the Science on
Human Genome Variation and "Race," Oct. 26, 2004; available at http://www.
genomecenter.howard.edu/News%20documents/Position%2OPaper%2010-24-04.pdf (last
visited Sept. 26, 2005) (suggesting that use of "race" for purposes of biomedical research is
inappropriate and serves to limit scientific advancement).
22 See National Human Genome Center at Howard University, Vision Statement,
available at http://www.genomecenter.howard.edu/intro.htm (last visited Nov. 16, 2005)
(detailing mission "to explore the science of and teach the knowledge about DNA sequence
variation and its interaction with the environment in the causality, prevention, and
treatment of diseases common in African American and other African Diaspora
populations").
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there was no source collecting this kind of data on African
Americans. In fact, before you hear about the issue of stem cells
being developed, you are going to hear a lot more about stem cells
and the lines approved by President Bush, the sixty some odd
lines that were approved for federal funding of research. Within
those sixty some odd lines, not one of them had been developed
from minorities; therefore, one of the concerns that folks at
Howard had is that we get to know the total variants of human
diversity.
So, "race," as most people think of it, is a social construct. It is
skin color, but from a scientific perspective, the true genetics
really needs to be more geographical ancestry. So, East Africans
are known to be slower metabolizers. There is a community in
Utah of very religious Catholics who were exhibiting diseases of
Eastern European Jews. A genetic and genealogical study was
done, which found that most of those families there actually had
Jewish roots because their families had converted to Catholicism
during the Inquisition. Such history of conversion was never
passed along through the families, and it was not until they all
got sick with these diseases here in Utah, that they were able to
go back and find that there was a genetic link; again, it is a
geographical basis. 23
There are many causes for health care disparities. Many of
you may know of the Tuskegee syphilis studies, 24 which lead to
strong distrust of science, scientists, and the government. This is
also one of the major reasons why African Americans do not
participate in drug trials. Culture, diet, socioeconomic status,
poverty and unemployment lead to healthcare disparities, access
to healthcare, exposure in the environment, education, and
discrimination. When minorities go to doctors, even minority
doctors, they often find that there is discrimination in the
approach and treatments. Stress is a major factor and, in fact,
studies have shown that those who live with discrimination on a
23 See generally April Lynch, Gene Tests Promising, Flawed as Breast Cancer Claims
Women, Screening Could Tell Why, SAN JOSE MERCURY NEWS, Dec. 21, 2004, at 1A
(detailing common mutated genes found Eastern European Jews).
24 See Debra J. Brown, Recruitment of Black Americans for Research: A Model of
Success, 10 J. MULTICULTURAL NURSING & HEALTH 3, Oct. 1, 2004, at 19 (commenting on
African American fear and distrust due to research based on differences in social history
and discriminatory treatment).
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regular basis live with higher levels of stress. That adds to more
health care disparities. 25
Dr. Loberg, who is the head of NitroMed, had told me that he
had a very hard time with his study on African Americans for
BiDil®. He had over a thousand people in the trials. This was
the largest trial on any heart failure drug for African Americans.
Prior to this, the largest number of minorities in a cardiology
clinical trial was seventy in a trial of six thousand patients. In
this case, with the help of many other groups, including the
Association of Black Cardiologists, 26 the National Medical
Association, 27  which represents black doctors, even the
Congressional Black Caucus, 28 the NitroMed trial was able to
enlist over a thousand patients and they did not lose one of them.
There was one hundred percent compliance.
So, the question is, with the human genome knowledge, can we
eliminate disparities? Yes so long as we focus on complex
diseases of the least healthy groups, and that study provides
insights into the causes of disparities, and that the benefits are
shared with the vulnerable populations. The message then goes
out to the minorities that science and medicine values the human
variation as an instrument of self-discovery. If we do not do that,
according to Dunston and Royal, we will exacerbate these
disparities. The benefits will be realized for only the affluent;
research is only for medical treatment of rare diseases. The
message becomes distorted and tells the minority groups that
they are inferior. Also, the science and the genetic knowledge
will just exacerbate the disparities, if used to further an image of
a single physical ideal of the typical white patient.
25 See David Williams, Discrimination, Oct. 1998, http://www.macses.ucsf.edu/
Research/Psychosociallnotebook/discrimination.html#Top (last visited Nov. 16, 2005)
(indicating correlation between stress levels experienced by minority individuals and
negative physical and mental reactions including increased blood pressure levels).
26 See Malcolm P. Taylor, Frequently Asked Questions About the A-Heft Trial
Background for ABC Members, http://abcardio.org/article-trial.html (last visited Nov. 16,
2005) (discussing partnership with NitroMed to sponsor all African American BiDil test).
27 See generally Randall Maxey, Healthcare Solutions for Black Americans, 96 J.
NAT'L. MED. Assoc. 2, 156-57 (2003) available at http://www.nmanet.org/156-159
jnma02O4.pdf (noting NMA's purpose of serving needs of physicians of African descent).
28 Elijah E. Cummings, Congressional Black Caucus, Message from the Chair,
available at http://www.congressionalblackcaucus.net (last modified Jan. 9, 2005)
(proclaiming itself the "conscience of Congress"); see BiDil for Treatment of Heart Failure
in American Americans, available at http://www.nitromed.com/BiDil.asp (last visited Nov.
16, 2005) (referring to involvement of members of Congressional Black Caucus in
NitroMed's BiDil research).
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There are other public policy and ethical issues. There is a
genetic non-discrimination bill that passed the Senate, 29 and that
will probably not pass the House. And I will end with a quote
from Dr. Collins just as a way of thanking him for his slides:
"Genetics is teaching us that there is no scientific basis for
drawing sharp boundaries around ethnic or racial groups. At the
DNA level, we are all ninety nine percent the same, all of us."30
29 See Kate Dalke, Genetic Nondiscrimination Bill Passes U.S. Senate, available at
http://www.genomenewsnetwork.org/articles/1O_03/s1O53.shtml (last modified Oct. 15,
2003) (reporting that Senate unanimously passed the bill).
30 See Lauren Crowley, Woodrow Wilson International Center for Scholars, Human
Genomics: Our Shared Inheritance, http://wwics.si.eduindex.cfm?topic-id=1414&fuse
action=newsitem&newsid=2150 (last visited Nov. 16, 2005) (discussing summary of Dr.
Collin's speech about genomics at the Wilson Center Director's Forum, noting that human
DNA is 99.9% the same from person to person).
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